Exposure to topiramate may not increase the risk of urolithiasis: A nationwide cohort study

• Topiramate exposure was assessed for first-time urolithiasis risk in Korea. • A nationwide population cohort from Korea was analyzed in this study for five years. • Topiramate exposure was not linked to higher urolithiasis incidence. • Findings support safer clinical decision-making regarding topiramate. • Real-world data suggest no increased stone risk with topiramate use. Although topiramate is mechanistically linked to an increased risk of urolithiasis, real-world evidence remains conflicting. This study aimed to evaluate the risk of a first-time episode of urolithiasis associated with topiramate exposure in the Korean population. Using the Korean National Health Insurance Service-National Sample Cohort, we identified participants from the 2015 national health screening. After excluding individuals with a prior diagnosis of urolithiasis, we performed 1:4 propensity score matching between patients with and without topiramate exposure. Matching variables included age, sex, body mass index, comorbidities, and a history of gout. Participants were followed longitudinally, and the risk of urolithiasis was assessed using Kaplan-Meier analysis and Cox proportional hazards regression. The final cohort included 1,560 patients exposed to topiramate and 6,240 matched controls who were followed for five years. During the follow-up period, urolithiasis was diagnosed in 47 patients (3.0%) in the topiramate group and 170 patients (2.7%) in the control group. The risk of developing urolithiasis was not significantly different between the two groups (p = 0.545). Furthermore, subgroup analyses stratified by current use or the cumulative duration of topiramate exposure also showed no significant associations. In this large, nationwide cohort, topiramate exposure was not associated with an increased risk of urolithiasis. Our findings suggest that in a real-world setting, the risk may not be as significant as suggested by its pharmacological mechanism.

Authors

Institutions

Publication Details

Journal
Epilepsy & Behavior Reports
Published
2026-03-01
DOI
https://doi.org/10.1016/j.ebr.2026.100864
Primary Topic
Kidney Stones and Urolithiasis Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exposure to topiramate may not increase the risk of urolithiasis: A nationwide cohort study

Woo-Seok Ha, Kimoon Chang
Epilepsy & Behavior Reports
Kidney Stones and Urolithiasis Treatments
article

Exposure to topiramate may not increase the risk of urolithiasis: A nationwide cohort study

Woo-Seok Ha, Kimoon Chang
article en

Abstract

• Topiramate exposure was assessed for first-time urolithiasis risk in Korea. • A nationwide population cohort from Korea was analyzed in this study for five years. • Topiramate exposure was not linked to higher urolithiasis incidence. • Findings support safer clinical decision-making regarding topiramate. • Real-world data suggest no increased stone risk with topiramate use. Although topiramate is mechanistically linked to an increased risk of urolithiasis, real-world evidence remains conflicting. This study aimed to evaluate the risk of a first-time episode of urolithiasis associated with topiramate exposure in the Korean population. Using the Korean National Health Insurance Service-National Sample Cohort, we identified participants from the 2015 national health screening. After excluding individuals with a prior diagnosis of urolithiasis, we performed 1:4 propensity score matching between patients with and without topiramate exposure. Matching variables included age, sex, body mass index, comorbidities, and a history of gout. Participants were followed longitudinally, and the risk of urolithiasis was assessed using Kaplan-Meier analysis and Cox proportional hazards regression. The final cohort included 1,560 patients exposed to topiramate and 6,240 matched controls who were followed for five years. During the follow-up period, urolithiasis was diagnosed in 47 patients (3.0%) in the topiramate group and 170 patients (2.7%) in the control group. The risk of developing urolithiasis was not significantly different between the two groups (p = 0.545). Furthermore, subgroup analyses stratified by current use or the cumulative duration of topiramate exposure also showed no significant associations. In this large, nationwide cohort, topiramate exposure was not associated with an increased risk of urolithiasis. Our findings suggest that in a real-world setting, the risk may not be as significant as suggested by its pharmacological mechanism.

Epilepsy & Behavior Reports
Eulji University (KR), Severance Hospital (KR), Gangnam Severance Hospital (KR)
Zero hunger
Openalex Percentile: Top 4%
Kidney Stones and Urolithiasis Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.